Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$2.28
+0.21 (+10.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-37321.00 · quality 62.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$133M
P/E
0.9x
↓EV/EBITDA
3.9x
↓ROE
-23.4%
↓Gross Margin
N/A
•Debt/Equity
-0.77
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $2.9M · FCF $9374.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $2.9M | $2.9M | $-3.2M | $-20.9M | $-9.2M |
| EBITDA | $3.1M | $3.1M | $-1.7M | $-19.6M | $-14.7M |
| EPS | 2.37 | 2.37 | -2.66 | -0.68 | -53.50 |
| Balance Sheet | |||||
| Debt/Equity | -0.77 | -0.77 | -0.45 | -0.46 | -3.73 |
| Current Ratio | 0.47 | 0.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $9374.00 | $9374.00 | $-37321.00 | $-4.2M | $-8.5M |
| Returns | |||||
| ROE | -23.4% | -23.4% | 20.8% | 175.8% | 721.0% |
| Valuation | |||||
| P/E | 0.91 | 0.91 | — | — | — |
| EV/EBITDA | 3.95 | 3.95 | — | — | — |
| Growth & Yield | |||||
| EPS Growth | 189.1% | 189.1% | -291.2% | 98.7% | — |
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-56.0%
EPS terminal req.
$0.20
Spread vs growth
245.1%
5Y implied EPS CAGR
-36.5%
EPS terminal req.
$0.24
Spread vs growth
225.6%
10Y implied EPS CAGR
-16.4%
EPS terminal req.
$0.39
Spread vs growth
205.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+812.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.66 → 2.37
Residual
+812.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.